Skip to content

Financial Report

As the global COVID-19 pandemic pushes on, National Jewish Health continues to pivot and adapt to the changing world around us. We are providing high throughput COVID and antibody testing services in Colorado as well as several surrounding states. We have provided thousands of patients and community members with much needed COVID-19 vaccines through our mass vaccine events without charge, and we have provided those children and adults suffering with the virus inpatient and outpatient acute care, needed medications, and a Center for Post-COVID Care and Recovery to care for their ongoing challenges. Our patients with other respiratory, cardiac, immune and related diseases have returned for much needed care.

Despite the ongoing pandemic, National Jewish Health had continued strong financial performance. While the pandemic limited patient visits, the strong performance of the reference laboratories helped drive increased patient revenues and improved collection rates. As a result, net patient service revenue grew over 20% to $178.5 million. Due to the strength of the National Jewish Health standalone clinical performance, revenue from joint ventures was lower than in previous years, but is expected to return to normal levels as the latest COVID-19 surge subsides. Researchers continue to be hard at work, receiving $57.3 million in grant revenues from federal and nonfederal sources, including a number of grants for the study and novel treatment of COVID-19.